A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (FD-TACT)
An Open-label, Randomised, Controlled, Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of a Fixed Dose Triple Artemisinin-based Combination Therapy (TACT) Artemether-lumefantrine-amodiaquine Versus First-line Artemisinin-based Combination Therapies (ACTs) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Sponsor: University of Oxford
This PHASE3 trial investigates Uncomplicated Plasmodium Falciparum Malaria and is currently actively recruiting participants. University of Oxford leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
5 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE3
Status: Unknown → Recruiting
-
Jul 2025 — Dec 2025 [monthly]
Unknown PHASE3
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Jul 2025 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .